Compare AXIL & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AXIL | COCH |
|---|---|---|
| Founded | 2015 | 1995 |
| Country | United States | United States |
| Employees | N/A | 47 |
| Industry | Package Goods/Cosmetics | Blank Checks |
| Sector | Consumer Discretionary | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.2M | 47.1M |
| IPO Year | 2017 | N/A |
| Metric | AXIL | COCH |
|---|---|---|
| Price | $6.95 | $0.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 11.1K | ★ 172.9K |
| Earning Date | 04-08-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $26,257,522.00 | N/A |
| Revenue This Year | N/A | $1.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $46.61 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.28 | $0.36 |
| 52 Week High | $10.25 | $1.91 |
| Indicator | AXIL | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 52.67 | 52.62 |
| Support Level | $6.75 | $0.64 |
| Resistance Level | $6.97 | $0.73 |
| Average True Range (ATR) | 0.20 | 0.05 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 26.67 | 71.87 |
AXIL Brands Inc is a company which is is a manufacturer and marketer of premium hearing enhancement and protection products, including ear plugs, earmuffs, and ear buds, and outdoor speakers, under the AXIL brand. AXIL delivers top hearing enhancement, protection, & audio devices. From ultra comfortable fitting processes, to stereo quality sound performance, to reliable & durable engineering. The company operates two operating segments: hearing enhancement and protection, and hair and skin care.
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.